Individuals required for a brain-implant trial by Musk’s company, Neuralink

Neuralink, Elon Musk’s brain-computer interface (BCI) company, has received FDA approval for its first human clinical trial and is recruiting participants with quadriplegia caused by ALS or spinal cord injury. The trial tests whether the company’s N1 implant, 64 flexible threads, thinner than a human hair, placed by a surgical robot into a brain region associated with movement intention, can let paralyzed patients control a computer cursor or type using thought alone. The device is wirelessly rechargeable and transmits decoded brain signals to a companion app. Neuralink has said it sought approval to implant roughly ten participants, though the final agreed number hasn’t been publicly disclosed.

Why it matters for healthcare executives

BCI trials are moving from research novelty to a real competitive regulatory race, and that has practical implications beyond neurology departments. Hospitals and rehabilitation systems that become trial sites gain a meaningful referral pipeline and visibility with patients living with ALS, spinal cord injury, and stroke-related paralysis — a small but high-need population that most systems struggle to serve well today. It’s also worth understanding the regulatory pathway differences: Neuralink’s N1 trial is an early feasibility study, while competitor Synchron is now working toward a pivotal trial aimed at a full FDA Premarket Approval (PMA) — the pathway that would actually make a BCI a commercially approved, reimbursable device rather than a research-only implant. For executives tracking where this technology could eventually intersect with covered care, PMA timelines are the more concrete signal to watch than press coverage of any single company.

Historical context

Neuralink is a comparatively late entrant. Blackrock Neurotech has been implanting BCI devices since 2004, two decades of clinical experience Neuralink doesn’t yet have. Precision Neuroscience takes a less invasive surgical approach, placing a thin, tape-like electrode array on the brain’s surface through a “cranial micro-slit” rather than threading electrodes into brain tissue. Synchron differs even further: its Stentrode device is implanted via a catheter through the blood vessels, avoiding open brain surgery entirely, a tradeoff of surgical simplicity against the signal resolution of directly implanted electrodes. Neuralink’s own approval process took years longer than the company initially expected, a point worth noting given Musk’s public timelines have historically run ahead of the company’s actual regulatory progress.

What’s changed since this announcement

Neuralink’s trial has since expanded well beyond the original recruiting phase, growing from a small initial cohort to dozens of participants across multiple trial sites, including an international arm in the UK (GB-PRIME, run with University College London Hospitals). The company has also received a second FDA Breakthrough Device Designation for a separate implant, called Blindsight, aimed at restoring visual perception in blind patients — a distinct program from the movement-control implant described here. Meanwhile, Synchron has continued advancing toward a pivotal trial targeting FDA approval, positioning it as a genuine contender to reach market before Neuralink.